Lincoln, Nebraska, Feb. 03, 2023 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRC) today announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, April 14, 2023, to shareholders of record as of the close of business on Friday, March 31, 2023.
For more than 40 years, NRC Health has been committed to achieving Human Understanding and bringing healthcare organizations closer to their customers than ever before by illuminating and improving the key moments that define an experience and build trust. Guided by their uniquely empathic heritage, proprietary methods, skilled associates, and holistic approach, NRC Health helps its customers design experiences that exceed expectations, inspire loyalty, and improve well-being among patients, residents, physicians, nurses, and staff.
| Last Trade: | US$13.78 |
| Daily Change: | 0.27 2.00 |
| Daily Volume: | 86,757 |
| Market Cap: | US$323.550M |
April 28, 2025 February 25, 2025 January 27, 2025 October 25, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
